223 related articles for article (PubMed ID: 26629769)
21. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
[TBL] [Abstract][Full Text] [Related]
22. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
23. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
24. [Trabectedin registry].
Kubácková K; Fínek J; Vyzula R; Zvaríková M; Vocka M; Batko S; Dreslerová J; Lazarov PP; Lysý M; Ptátková Z; Benesová V; Bortlícek Z; Kandrnal V
Klin Onkol; 2011; 24(6):470-4. PubMed ID: 22257238
[TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
Barone A; Chi DC; Theoret MR; Chen H; He K; Kufrin D; Helms WS; Subramaniam S; Zhao H; Patel A; Goldberg KB; Keegan P; Pazdur R
Clin Cancer Res; 2017 Dec; 23(24):7448-7453. PubMed ID: 28774898
[TBL] [Abstract][Full Text] [Related]
26. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Grosso F; D'Ambrosio L; Zucchetti M; Ibrahim T; Tamberi S; Matteo C; Rulli E; Comandini D; Palmerini E; Baldi GG; DeCensi A; Bergaglio M; Marra D; Marchesi E; Siri G; D'Incalci M; Grignani G
Cancer; 2020 Nov; 126(21):4726-4734. PubMed ID: 32749681
[TBL] [Abstract][Full Text] [Related]
28. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
Sanfilippo R; Dileo P; Blay JY; Constantinidou A; Le Cesne A; Benson C; Vizzini L; Contu M; Baldi GG; Dei Tos AP; Casali PG
Anticancer Drugs; 2015 Jul; 26(6):678-81. PubMed ID: 25763543
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
[TBL] [Abstract][Full Text] [Related]
30. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Saponara M; Stacchiotti S; Gronchi A
Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
[TBL] [Abstract][Full Text] [Related]
32. [An Effective Treatment of Relapsed Leiomyosarcoma with Fourth-Line Trabectedin].
Nozaki Y; Yamaguchi S; Takagi T; Kato S
Gan To Kagaku Ryoho; 2019 Feb; 46(2):275-277. PubMed ID: 30914533
[TBL] [Abstract][Full Text] [Related]
33. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.
Hollebecque A; Adenis A; Taieb S; Lebedinsky C; Penel N
Invest New Drugs; 2010 Aug; 28(4):529-30. PubMed ID: 19430728
[No Abstract] [Full Text] [Related]
34. Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.
Baldi GG; Di Donato S; Fargnoli R; Dona M; Bertulli R; Parisi E; Fantini L; Sbaraglia M; Panella M
Anticancer Drugs; 2016 Oct; 27(9):908-13. PubMed ID: 27348763
[TBL] [Abstract][Full Text] [Related]
35. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Monk BJ; Dalton H; Benjamin I; Tanović A
Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
[TBL] [Abstract][Full Text] [Related]
36. Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?
Grivas A; Trafalis DT; Thanopoulou E; Ziras NG; Athanasiou AE
J BUON; 2010; 15(4):791-3. PubMed ID: 21229647
[TBL] [Abstract][Full Text] [Related]
37. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
38. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
39. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma.
Pink D; Bertz-Lepel J; Busemann C; Bitz U; Reichardt P
Onkologie; 2012; 35(5):249-52. PubMed ID: 22868503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
